ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

02-May-2022 - ViGeneron GmbH, a next-generation gene therapy start up, announced a follow-on collaboration with Daiichi Sankyo Company, Limited to utilize ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address an undisclosed target for the treatment of prevalent eye ...

Start-up ViGeneron announces research collaboration with Daiichi Sankyo

Evaluate vgAAV for novel ophthalmic gene therapy

19-Jan-2021 - ViGeneron GmbH, a gene therapy company, announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited, for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic ...

ViGeneron and Biogen collaborate

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

05-Jan-2021 - ViGeneron GmbH announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV ...

ViGeneron closes of series A financing to drive development of next generation gene therapy pipeline

02-Dec-2019 - ViGeneron GmbH announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy ...